| Title: |
Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study |
| Authors: |
Souza, WM; Amorim, MR; Sesti-Costa, R; Coimbra, LD; Brunetti, NS; Toledo-Teixeira, DA; de Souza, GF; Muraro, SP; Parise, PL; Barbosa, PP; Bispo-dos-Santos, K; Mofatto, LS; Simeoni, CL; Claro, IM; Duarte, ASS; Coletti, TM; Zangirolami, AB; Costa-Lima, C; Gomes, ABSP; Buscaratti, LI; Sales, FC; Costa, VA; Franco, LAM; Candido, DS; Pybus, OG; de Jesus, JG; Silva, CAM; Ramundo, MS; Ferreira, GM; Pinho, MC; Souza, LM; Rocha, EC; Andrade, PS; Crispim, MAE; Maktura, GC; Manuli, ER; Santos, MNN; Camilo, CC; Angerami, RN; Moretti, ML; Spilki, FR; Arns, CW; Addas-Carvalho, M; Benites, BD; Vinolo, MAR; Mori, MAS; Gaburo, N; Dye, C; Marques-Souza, H; Marques, RE |
| Publisher Information: |
Elsevier |
| Publication Year: |
2021 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Background Mutations accrued by SARS-CoV-2 lineage P.1—first detected in Brazil in early January, 2021—include amino acid changes in the receptor-binding domain of the viral spike protein that also are reported in other variants of concern, including B.1.1.7 and B.1.351. We aimed to investigate whether isolates of wild-type P.1 lineage SARS-CoV-2 can escape from neutralising antibodies generated by a polyclonal immune response. Methods We did an immunological study to assess the neutralising effects of antibodies on lineage P.1 and lineage B isolates of SARS-CoV-2, using plasma samples from patients previously infected with or vaccinated against SARS-CoV-2. Two specimens (P.1/28 and P.1/30) containing SARS-CoV-2 lineage P.1 (as confirmed by viral genome sequencing) were obtained from nasopharyngeal and bronchoalveolar lavage samples collected from patients in Manaus, Brazil, and compared against an isolate of SARS-CoV-2 lineage B (SARS.CoV2/SP02.2020) recovered from a patient in Brazil in February, 2020. Isolates were incubated with plasma samples from 21 blood donors who had previously had COVID-19 and from a total of 53 recipients of the chemically inactivated SARS-CoV-2 vaccine CoronaVac: 18 individuals after receipt of a single dose and an additional 20 individuals (38 in total) after receipt of two doses (collected 17–38 days after the most recent dose); and 15 individuals who received two doses during the phase 3 trial of the vaccine (collected 134–230 days after the second dose). Antibody neutralisation of P.1/28, P.1/30, and B isolates by plasma samples were compared in terms of median virus neutralisation titre (VNT50, defined as the reciprocal value of the sample dilution that showed 50% protection against cytopathic effects). Findings In terms of VNT50, plasma from individuals previously infected with SARS-CoV-2 had an 8·6 times lower neutralising capacity against the P.1 isolates (median VNT50 30 [IQR |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1016/s2666-5247(21)00129-4 |
| Availability: |
https://doi.org/10.1016/s2666-5247(21)00129-4; https://ora.ox.ac.uk/objects/uuid:297795b6-2e3e-45c9-9bf4-ad532ae0c8a2 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) |
| Accession Number: |
edsbas.884028CF |
| Database: |
BASE |